AI Investments: U.S. Export Controls & National Security Risks
by
August 6, 2026
Investors can’t get enough of investments in AI-related businesses, but this Weil memo reminds prospective investors that where target is based in or has significant ties to China, a distinct set of U.S. export control and national security considerations specifically targeting the AI sector need to be taken into account. This excerpt provides an overview of the topics addressed in the memo:
– The U.S. Department of Commerce’s Bureau of Industry and Security’s (BIS) Foreign Direct Product Rule (FDPR) elevates risks for investments into non-U.S. AI-sector targets whose products, models, or infrastructure depend on U.S.-origin chips, chip design software, or manufacturing equipment.
– BIS is expected to expand export controls beyond just hardware to cover AI computing services and, potentially, model weights and capabilities, which could directly restrict U.S. parties from engaging with AI businesses with a significant nexus to China.
– Graphics Processing Units (GPU) and advanced-chip export licensing is currently governed by a patchwork of narrower rules following the rescission of the AI Diffusion Rule, with a reported draft framework from BIS that would tie licensing to compute cluster size.
– Any Chinese target carries elevated risk of being designated as a restricted party, which could sever access to U.S.-origin technology, U.S. customers, and U.S. investors if triggered.
The memo recommends that investors review the target’s hardware, software, cloud, and supply chain dependencies, as well as its reliance on U.S. customers, as part of the due diligence process in order to assess exposure to U.S. export controls and commercial restrictions. In addition, the diligence should also evaluate potential risks arising from the target’s, its affiliates’, or key suppliers’ ties to the PRC government or military-linked entities. The memo cautions that regulatory landscape is evolving, and that deal terms should incorporate the flexibility to respond to adverse regulatory developments.